Oteseconazole (VT-1161)
Sponsors
Mycovia Pharmaceuticals Inc.
Conditions
Recurrent Vulvovaginal Candidiasis
Phase 3
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
CompletedNCT03561701
Start: 2018-08-23End: 2021-08-03Updated: 2026-02-17
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
CompletedNCT03562156
Start: 2018-08-16End: 2021-08-06Updated: 2026-02-17